A systematic review on richter syndrome: What is the published evidence?

Leukemia and Lymphoma

Volumn 51, Issue 3, 2010, Pages 415-421

  Molica, Stefano ^a  

^a PUGLIESE CIACCIO HOSPITAL   (Italy)

Author keywords

CLL; Richter syndrome; Systematic review

Indexed keywords

ALEMTUZUMAB; CD38 ANTIGEN; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; FLUDARABINE; IBRITUMOMAB TIUXETAN; METHOTREXATE; OXALIPLATIN; PENTOSTATIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; CLINICAL TRIAL; DRUG DOSE INCREASE; GENE EXPRESSION; GENOTYPE; HISTOPATHOLOGY; HUMAN; PRIORITY JOURNAL; PROGNOSIS; RICHTER SYNDROME; SALVAGE THERAPY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEM CELL TRANSPLANTATION; SYNDROME; SYSTEMATIC REVIEW; TELOMERE; BIOPSY; CLINICAL TRIAL (TOPIC); COMPLICATION; DISEASE COURSE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA; METASTASIS; PATHOLOGY; RISK FACTOR; TREATMENT OUTCOME;

BIOPSY; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA; NEOPLASM METASTASIS; PROGNOSIS; RISK FACTORS; SYNDROME; TREATMENT OUTCOME;

EID: 77249170762     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903515192     Document Type: Article

References (32)

1. Richter MN. Generalized reticular cell sarcoma of lymph nodes associated with lymphatic leukemia. Am J Pathol 1928;4:285-292.
2. Lortholary P, Boiron M, Ripault J, Levy JP, Manus A, Bernard J. Chronic lymphoid leukemia secondarily associated with a malignant reticulopathy: Richter's syndrome. Nouv Rev Fr Hematol 1964;78:621-644.
3. Tsimberidou AM, Keating MJ. Richter syndrome: biology, incidence, and therapeutic strategies. Cancer 2005;103:216-228.
4. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute- Working Group 1996 guidelines. Blood 2008;111: 5446-5456.
5. Maddocks-Christianson K, Slager SL, Zent CS, et al. Risk factors for development of a second malignancy in patients with chronic lymphocytic leukemia. Br J Haematol 2007; 139:398-404.
6. Rossi D, Cerri M, Capello D, et al. Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. Br J Haematol 2008;142:202-215.
7. Cheson BD, Vena DA, Barrett J, Freidlin B. Second malignancies as consequence of nucleoside analog therapy for chronic. J Clin Oncol 1999;17:2454-2460.
8. Schöllkopf C, Rosendahl D, Rostgaard K, Pipper C, Hjalgrim H. Risk of second cancer after chronic lymphocytic leukemia. Int J Cancer 2007;121:151-156.
9. Tsimberidou AM, Wen S, McLaughlin P, et al. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol 2009;27:904-910.
10. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukemia (the LRF CLL4 Trial): a randomized controlled trial. Lancet 2007;370:230-239.
11. Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005;23:4070-4078. (Pubitemid 46211312)
12. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079-4088. (Pubitemid 46211313)
13. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;25:5616-5623.
14. Stilgenbauer S, Zenz T, Winkler D, et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the german chronic lymphocytic leukemia study group. J Clin Oncol 2009;27:3994-4001.
15. von Elm E, Costanza MC, Walder B, Tramer MR. More insight into the fate of biomedical meeting abstracts: a systematic review. BMC Med Res Method 2003;3:12-18.
16. Tsimberidou A-M, O'Brien S, Khouri I, et al. Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol 2006;24: 2343-2351.
17. Mauro FR, Foa R, Giannarelli D, et al. Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. Blood 1999;94:448-454.
18. Thornton PD, Bellas C, Santon A, et al. Richter's transformation of chronic lymphocytic leukemia. The possible role of fludarabine and the Epstein-Barr virus in its pathogenesis. Leukemia Res 2005;29:389-395.
19. Robak T, Blonski JZ, Gora-Tybor J, et al. Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine. Eur J Cancer 2004;40:383-389. (Pubitemid 38121276)
20. Aydin S, Rossi D, Bergui L, et al. CD38 gene polymorphism and chronic lymphocytic leukemia: a role in transformation to Richter syndrome? Blood 2008;111:5646-5653.
21. Rossi D, Drandi D, Genuardi E, et al. Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia. Leukemia 2009;23:1062-1072.
22. Rossi D, Spina V, Cerri M, et al. Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. Clin Cancer Res. 2009;15:4415-4422.
23. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-282.
24. Mao Z, Quintanilla-Martinez L, Raffeld M, et al. IgVH mutational status and clonality analysis of Richter's transformation. Am J Surg Pathol 2007;31:1605-1614.
25. Cobo F, Rosiñol L, Mart?́nez A, et al. Limitations of Gallium- 67 SPECT in histological transformation of chronic lymphocytic leukaemia: an analysis of 13 patients with clinically suspected Richter's syndrome. Br J Haematol 2002;119:484-487.
26. Bruzzi JF, Macapinlac H, Tsimberidou AM, et al. Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT. J Nucl Med 2006;47:1267-1273.
27. Omoti CE, Omoti AE. Richter syndrome: a review of clinical, ocular, neurological and other manifestations. Br J Haematol 2008;142:709-716.
28. Parrens M, Sawan B, Dubus P, et al. Primary digestive Richter's syndrome. Modern Pathol 2001;14:452-457.
29. Dabaja BS, O'Brien SM, Kantarjian HM, et al. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyper-CVXD) regimen in Richter's syndrome. Leuk Lymphoma 2001;42:329-337.
30. Tsimberidou AM, Kantarjian HM, Cortes J, et al. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocytemacrophage- colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GMCSF in patients with Richter syndrome or fludarabine refractory chronic lymphocytic leukemia. Cancer 2003;97: 1711-1720.
31. Tsimberidou AM, Wierda WG, Plunkett W, et al. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2008;26:196-203.
32. Tsimberidou AM, Murray JL, O'Brien S, Wierda WG, Keating MJ. Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome. Cancer 2004;100:2195-2200.